PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials (Q35530872)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 2014

Language	Label	Description	Also known as
English	PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials	scientific article published on December 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5 references

21 March 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

0 references

PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

inflammatory bowel diseases

5 references

21 March 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

biomedical investigative technique

1 reference

19 September 2019

monoclonal antibody

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

0 references

author name string

Man Cai Wang

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ling Yi Zhang

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Wei Han

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Yuan Shao

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mo Chen

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Rui Ni

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Gen Nian Wang

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ya Wu Zhang

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Xiao Dong Xu

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

You Cheng Zhang

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

0 references

publication date

1 December 2014

6 references

Europe PubMed Central

PubMed publication ID

8 August 2017

21 March 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

6 references

21 March 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

93

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

e326

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

copyright license

Creative Commons Attribution 4.0 International

5 references

Europe PubMed Central

21 March 2019

Europe PubMed Central

19 September 2019

Europe PubMed Central

27 September 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

13 December 2019

copyright status

0 references

on focus list of Wikimedia project

0 references

Vedolizumab as induction and maintenance therapy for Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Vedolizumab as induction and maintenance therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

A clinical review of recent findings in the epidemiology of inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

New and emerging treatments for ulcerative colitis: a focus on vedolizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Recent developments in the treatment of inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Vedolizumab for Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Novel targets for inflammatory bowel disease therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Targeting T-cell migration in inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Review article: loss of response to anti-TNF treatments in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Asymptomatic reactivation of JC virus in patients treated with natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Unravelling the pathogenesis of inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Natalizumab for induction of remission in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

T-cell homing specificity and plasticity: new concepts and future challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Natalizumab for active Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Medical therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Corticosteroids in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

27 July 2018

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Inhibition of leukocyte trafficking in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603082

26 September 2018

Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25526490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/25526490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MD.0000000000000326

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25526490%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35530872&oldid=1644969682"